WAKEFIELD, MA, Aug. 5 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. , a developer and manufacturer of medical products that fight infection and inflammation, announced plans to release its financial results for the second quarter 2008 on Tuesday, August 12, 2008.
The company will host a conference call at 9:00 AM ET on Wednesday, August 13, 2008 to discuss the financial results for the quarter.
In addition to the standard disclosure over wire services, a news release and financial statements will be posted on the NUCRYST website.
About NUCRYST Pharmaceuticals
NUCRYST Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by pain, infection and inflammation. The Company has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101 for use in medical devices and as an active pharmaceutical ingredient.
Acticoat(TM) is a trademark of Smith & Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
CONTACT: David B. Holtz, Vice President and Chief Financial Officer,
NUCRYST Pharmaceuticals, (781) 224-1444, info@nucryst.com; Gregory W. Gin,
Lazar Partners, (212) 867-1762
